

منابع آزمون های ارتقا - گواهینامه و دانشنامه تخصصی ۱۴۰۳

رشته پزشکی هسته ای	ردیف
<p>1. Nuclear Cardiology and Multimodal Cardiovascular Imaging: A Companion to Braunwald's Heart Disease 1st Edition. Marcelo Fernando Di Carli, 2022 (except for these chapters: 1, 2, 30, 31, 32).</p> <p>2. Physics and Radiobiology of Nuclear Medicine; GB Saha, Springer, 2013.</p> <p>3. Fundamentals of Body CT; W. Richard Webb: 5th Edition, 2019.</p> <p>4. Fundamentals of Nuclear Pharmacy; GB Saha, Springer, 2018. [Only these chapters: 1.3, 2, 4 (except 4.3 and 4.4), 5, 6, 7, 8, 11.2.6, 11.2.7, 11.2.8, 11.2.9, 11.2.10, 11.4.5, 12, 13, 15, 16]</p> <p>5. Volterrani D, et al. Nuclear Medicine Textbook: Methodology and Clinical Applications, Springer; 2019.(only these chapters: 8, 14, 15, 18, 19, 22, 23, 24, 25, 26, 28, 30, 32, 33, 34, 35, 36, 38, 47, 48, 49, 50)</p> <p>6. Ali Gholamrezanezhad et al. Radiology-Nuclear Medicine Diagnostic Imaging, A Correlative Approach, 2023. (except for these chapters: 2, 3, 4, 7, 8, 11, 12, 14, 18, 20, 22, 28, 31)</p>	۱۳
<p>Guidelines</p> <ol style="list-style-type: none"> 1. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0 (2020) 2. The SNMMI and EANM procedural guidelines for diuresis renography in infants and children (2018) 3. SNMMI procedure standard/EANM practice guideline for diuretic renal scintigraphy in adults with suspected upper urinary tract obstruction 1.0 (2018) 4. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 50, pages1466–1486 (2023) 5. Kevin J. Donohoe et al. Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema. Society of Nuclear Medicine and Molecular Imaging. (2023). 6. Haugen BR, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan; 26(1):1-133. 7. Francis GL, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul;25(7):716-59. 8. Ross DS, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421 (2016). 	مجلات

9. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. *Thyroid*. March 2017, 27(3): 315-389.
10. Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT). *European Journal of Nuclear Medicine and Molecular Imaging.*, 50, pages 2830–2845 (2023).
11. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer (2018)
12. EANM guideline for ventilation/perfusion SPECT for diagnosis of pulmonary embolism and beyond (2019)
13. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy *Clin Nucl Med*. Jun 1;47(6):503-511. (2022)
14. SNMMI procedure standard/EANM practice guideline for palliative nuclear medicine therapies of bone metastases (2023).
15. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *Eur J Nucl Med Mol Imaging*. Apr; 49(5):1682-1699. (2022).
16. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. *J Nucl Med* (2023)
17. The EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma (2019)
18. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F] FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. *European Journal of Nuclear Medicine and Molecular Imaging*. 49, pages, 2323–2341 (2022).
19. EANM guideline on the role of 2-[¹⁸F] FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA) (2021)
20. ASNC AND EANM cardiac amyloidosis practice points: ^{99m}Techetium- 3,3-diphosphono- 1,2-propanodicarboxylic acid (DPD) and ^{99m}Techetium hydroxymethylene diphosphonate (HMDP) imaging for transthyretin cardiac amyloidosis (2019)
21. National Osteoporosis Foundation (NOF) / International Society for Clinical Densitometry (ISCD) FRAX Implementation Guide (2019)
22. Hologic, Inc. Advanced Body Composition, Reporting and Interpretation: A Technical Discussion (2009)
23. The International Society for Clinical Densitometry (ISCD) official position for adults (2019)
24. The International Society for Clinical Densitometry (ISCD) official position for pediatrics (2019)

Articles in Journals

1. Mendichovszky I, Solar BT, Smeulders N, Easty M, Biassoni L. Nuclear medicine in pediatric nephro-urology: An Overview. *Semin Nucl Med.* 2017 May;47(3):204-228.
2. Martineau P, Bazarjani S, Zuckier LS. Artifacts and incidental findings encountered on dual-energy x-ray absorptiometry: Atlas and analysis. *Semin Nucl Med.* 2015;45(5):458-69.
3. Agrawal K, Esmail AA, Gnanasegaran G, Navalkisoor S, Mittal BR, Fogelman I. Pitfalls and limitations of radionuclide imaging in endocrinology. *Semin Nucl Med.* 2015 Sep;45(5):440-57.
4. Schreuder N, Koopman D, Jager PL, Kosterink JGW, van Puijenbroek E. Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. *Semin Nucl Med.* 2019 Sep;49(5):382-410.
5. Carrasquillo JA et al. Imaging of pheochromocytoma and paraganglioma. *J Nucl Med* 2021; 62:1033–1042.
6. Carrasquillo JA et al. Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma. *J Nucl Med* 2021; 62:1192–1199.
7. <https://doi.org/10.2967/jnumed.121.262402>.
8. Volkan-Salanci B et al. Imaging in renal transplants: An update. *Seminars in Nuclear Medicine.* 2021;51(4):364-379.
9. Del Olmo-García MI et al. Prevention and management of hormonal crisis during theragnosis with Lu-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. *J Clin Med.* 2020 Jul 12;9(7):2203.
10. Mihailovic J et al. PET/CT Variants and Pitfalls in Head and Neck Cancers Including Thyroid Cancer. *Seminars in Nuclear Medicine.* 2021;51(5):419-440.
11. Lopci E et al. PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma. *Seminars in Nuclear Medicine.* 2021;51(5):458-473.
12. EG et al. PET/CT Variants and Pitfalls in Breast Cancers. *Seminars in Nuclear Medicine.* 2021;51(5):474-484.
13. Jayaprakasam VS et al. Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. *Seminars in Nuclear Medicine.* 2021;51(5):485-501
14. Arslan E et al. PET/CT Variants and Pitfalls in Liver, Biliary Tract, Gallbladder and Pancreas. *Seminars in Nuclear Medicine.* 2021;51(5):502-518.
15. Imperiale A et al. Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. *Seminars in Nuclear Medicine.* 2021;51(5):519-528.

- | | | |
|---|--|--|
| <p>16. Pilkington P et al. FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):554-571.</p> <p>17. Agrawal A et al. PET/CT Normal Variants and Pitfalls in Pediatric Disorders. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):572-583.</p> <p>18. Benz MR et al. PET/CT Variants and Pitfalls in Bone and Soft Tissue Sarcoma. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):584-592.</p> <p>19. Dejanovic D et al. PET/CT Variants and Pitfalls in Gynecological Cancers. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):593-610.</p> <p>20. Vasireddi A et al. PET/CT Limitations and Pitfalls in Urogenital Cancers. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):611-620.</p> <p>21. Mei R et al. PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):621-632.</p> <p>22. Pijl JP et al. Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):633-645.</p> <p>23. UJ et al. Pitfalls on PET/CT Due to Artifacts and Instrumentation. <i>Seminars in Nuclear Medicine</i>. 2021;51(6):646-656.</p> | | |
|---|--|--|